【摘要】 目的观察低剂量吉西他滨联合卡铂治疗晚期非小细胞肺癌患者的临床疗效及对生活质量的影响。方法96例晚期非小细胞肺癌患者随机分为两组。对照组采用吉西他滨1000mg/m2,静脉滴注30min,第1、8天,卡铂300mg/m2,第1天;治疗组采用吉西他滨250mg/m2,6h静脉持续滴注,第1、8天,卡铂同上。每3周为1个疗程。治疗2个疗程后进行疗效评价。采用EORTCQLQ-C30和QLQ-LC13问卷对治疗前、后症状和生活质量的改变进行评价。结果总有效率、中位生存期、临床缓解时间、1年生存率两组对比无显著性差异(P均>0.05);治疗组Ⅲ-Ⅳ度白细胞下降及恶心呕吐的发生率明显低于对照组(P<0.05);两组生存质量各领域包括功能子领域及症状子领域评分治疗后明显改善,治疗组改善更明显。结论低剂量吉西他滨联合卡铂治疗晚期非小细胞肺癌疗效确切、不良反应轻,能显著改善晚期非小细胞肺癌患者的生活质量。更多还原

【Abstract】 Objective To observe the clinical effect of low-dose gemcitabin combined with carboplatin in the treatment of advanced non-small cell lung cancer(NSCLC)and its influence on the quality of life (QOL).Methods 96 cases of advanced NSCLC were randomly divided into two groups. The control group received 1 000 mg/m2 gemcitabin intravenous drip in half an hour at day 1 and 8,and 300 mg/m2 carboplatin at day 1.The treatment group underwent the therapy of 250 mg/m2 gemcitabin for six hours at day 1 and 8,and the same to carboplatin. The clinical efficacy was evaluated after two cycles of chemotherapy. The impact of treatment on disease-related symptoms and QOL were evaluated by EORTC QLQ-C30 and QLQ-LC13.Results There were no significantly difference between the two groups,including total effective rate,one year survival rate,median survival rate and disease median response time (all P>0.05). WHO grade Ⅲ-Ⅳ leucopenia,nausea and vomiting occurred in the control group was higher than that in the treatment group. QOL in the two groups were improved after treatment with the improvement of scores in all domains,including functional and symptom sub-domain,and the treatment group improved more significant than that the control group.Conclusion Low-dose gemcitabine combined with carboplatin is a relatively safe and effective regimen for patients with advanced NSCLC. It can improve the QOL and symptoms of advanced NSCLC patients.更多还原